rss
Arch Dis Child 2004;89:745-750 doi:10.1136/adc.2003.035980
  • Community child health, public health, and epidemiology

Juvenile thyrotoxicosis; can we do better?

  1. G Birrell,
  2. T Cheetham
  1. Department of Paediatrics, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK
  1. Correspondence to:
    Dr T D Cheetham
    Children’s Out Patient Department, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK; t.d.cheethamncl.ac.uk
  • Accepted 4 December 2003

Abstract

Thyrotoxicosis remains a frustrating condition for the young person, family, and health professionals involved. The associated symptoms do not always suggest thyroid disease and patients can be unwell for many months before the diagnosis is made. The antithyroid drug regimen used to treat children and adolescents with thyrotoxicosis varies from one unit to another and yet the potentially life threatening side effects and remission rates post-treatment may be related to the regimen used. Most patients with thyrotoxicosis will need many years of drug therapy if the thyroid gland is not removed surgically or destroyed by radioiodine. Even “definitive” treatment will typically necessitate thyroxine replacement for life.

Footnotes

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

    ADC is co-owned by the RCPCH and is the official journal of the European Academy of Paediatrics